Results 111 to 120 of about 143,857 (295)

Repercussions of NSAIDS drugs on bone tissue: the osteoblast [PDF]

, 2015
Non-steroidal anti-inflammatory drugs (NSAIDs) can act by modulating the behavior of osteoblasts, including their proliferation, differentiation, adhesion, and migration, but not all NSAIDs have these effects.
Ruiz Rodríguez, Concepción, Luna Bertos, María Elvira De, Manzano-Moreno, Francisco Javier, García Martínez, Olga, Ramos Torrecillas, Javier   +4 more
core   +1 more source

High‐Resolution Deep Learning Dixon Magnetic Resonance Imaging of the Sacroiliac Joints Is Noninferior to Standard Magnetic Resonance Imaging in Patients With Suspected Axial Spondyloarthritis

Arthritis &Rheumatology, EarlyView.
Objective To compare the multisequence standard magnetic resonance imaging (sMRI) protocol of the sacroiliac joints with a single high‐resolution deep learning–reconstructed Dixon sequence (DL‐Dixon) in patients with suspected axial spondyloarthritis (axSpA). Methods Seventy‐six patients with chronic low back pain and suspected axSpA underwent clinical,
Dominik Deppe, Mariam Koka, Fabian Proft, Sevtap Tugce Ulas, Kay‐Geert Hermann, Denis Poddubnyy, Mikhail Protopopov, Henriette Baum, Hildrun Haibel, Mehrgan Shahryari, Valeria Rios Rodriguez, Jens Vogel‐Claussen, Torsten Diekhoff   +12 more
wiley   +1 more source

Determinants of Difficult‐to‐Manage and Treatment‐Refractory Axial Spondyloarthritis: A Cross‐Sectional Analysis Within a Longitudinal Cohort

Arthritis &Rheumatology, EarlyView.
Objective The purpose of this study was to estimate the prevalence of difficult‐to‐manage (D2M) and treatment‐refractory (TR) axial spondyloarthritis (axSpA) and to identify factors associated with D2M and TR disease in a longitudinal cohort. Methods We performed a cross‐sectional analysis on data from the Schroeder Arthritis Institute Spondylitis ...
Patricia Remalante‐Rayco, Laura Passalent, Tina Chim, Hannah Vijayan, Manal Alnasser, Zeynep Baskurt, Robert D. Inman, Nigil Haroon, Denis Poddubnyy   +8 more
wiley   +1 more source

Analysis on cardiovascular risk of nsaids

, 2019
emerging with brief introduction about history and development of nsaids, mechanism of action and classification,thesis was focusing mainly on the cardiovascular risk of the nsaids, and the selective nsaids in a higher extent, presenting the mechanism of
Sabagh, Tareq
core  

Deep Immunophenotyping Reveals Distinct Immune Signatures in Axial Spondyloarthritis and Psoriatic Arthritis

Arthritis &Rheumatology, EarlyView.
Objective Axial spondyloarthritis (axSpA) and psoriatic arthritis (PsA) are overlapping yet distinct conditions within the SpA spectrum. As divergent immunophenotypes may influence disease course and therapeutic response, we compared immune cell subsets, cytokine profiles, and inflammatory mediators.
Natalie Frede, Nils Craig‐Müller, Silke Kohrt, Marei‐Theresa Bott, Ulrich Salzer, Ana Cecilia Venhoff, Jens Thiel, Julia Frede, Reinhard E. Voll, Marta Rizzi, Raquel Lorenzetti, Nils Venhoff   +11 more
wiley   +1 more source

Effekter av PPARδ agonist og NSAIDs i cellelinjer fra coloncancer : Medieres effekter av NSAIDs via PPARδ? [PDF]

, 2009
Epidemiologiske og eksperimentelle data tyder på at ikke-steroide antiinflammatoriske midler (NSAIDs) kan redusere risikoen for kreft. Det er antatt at denne effekten skyldes hemming av cyklooksygenase (COX) og dermed redusert prostaglandinproduksjon ...
Dugstad, Marie
core  

Deucravacitinib in Active Psoriatic Arthritis: Efficacy and Safety Up to 52 Weeks From the Randomized, Double‐Blind, Phase 3 POETYK PsA‐2 Trial

Arthritis &Rheumatology, EarlyView.
Objective To assess the efficacy and safety of deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, in patients with psoriatic arthritis (PsA) who were naive to biologic disease‐modifying antirheumatic drugs or received tumor necrosis factor inhibitors. Methods In the 52‐week, double‐blind, placebo‐controlled, phase 3 Program for Evaluation
Philip J. Mease, Vinod Chandran, April W. Armstrong, Ricardo Blanco, Alexis Ogdie, Evan L. Siegel, Alice B. Gottlieb, Xiaofeng Zeng, Diamant Thaçi, Mitsumasa Kishimoto, Hendrik Schulze‐Koops, Alan Kivitz, Eva Dokoupilová, Akimichi Morita, Eric M. Ruderman, Michael Plewinski, Kejia Wang, Caroline Sardinas, Eleni Vritzali, John Vaile, Atul Deodhar   +20 more
wiley   +1 more source

Comparison of NSAIDs activity in COX-2 expressing and non-expressing 2D and 3D pancreatic cancer cell cultures

, 2018
Ugnė Čeponytė, Miglė Paškevičiū tė, Vilma Petrikaitė Department of Drug Chemistry, Faculty of Pharmacy, Lithuanian University of Health Sciences, Kaunas, Lithuania Purpose: In this study, we evaluated the anticancer activity of non-steroidal
Čeponytė U, Petrikaitė V, Paškevičiūtė M   +2 more
core  

Risk of Cancer According to Duration of Targeted Therapy Exposure in Spondyloarthritis: A Nationwide Cohort Study From the French Health Insurance Database

Arthritis &Rheumatology, EarlyView.
Objective To assess the association between duration of targeted therapy exposure and cancer risk in patients with spondyloarthritis (SpA), including those with psoriatic arthritis, axial SpA, and other subtypes. Methods This nationwide cohort study used the French health insurance database to identify adults with SpA initiating a targeted therapy ...
Karine Tankovic, Pascal Claudepierre, Tat Thang Vo, Tran Trong Khoi Le, Siham Iggui, Laetitia Penso, Emilie Sbidian, Laura Pina Vegas   +7 more
wiley   +1 more source

Formulation and in-vitro evaluation of oxaprozin transdermal patches for sustained anti-inflammatory therapy

Journal of Applied Pharmaceutical Research
Background: Inflammation is characterized by pain, altered membrane permeability, increased vascular activity, and protein denaturation. Oxaprozin, a BCS Class II NSAID, is often used to manage inflammation and pain but is limited by poor solubility and ...
Mansi Gupta, Priya Tiwari
doaj   +1 more source